#bladder mesh erosion

[productiveandfree]

Older Women in the Workforce: Common Productivity Challenges and Ways to Overcome

One of the most important assets available to organizations is diversity and inclusivity. It refers to a workforce comprising people of different ethnicities, social and economic backgrounds, and age groups. 

This type of workplace can have several benefits, such as mentorship, adaptation to change, a broader skill base, and increased productivity. The Harvard Business Review offers us a glimpse of the forgotten dimension of diversity. It states that companies hiring with this as their end goal also succeed in retaining employee commitment and satisfaction. 

In this article, we will focus exclusively on older women. This demographic has much to offer to a workplace due to experience and expertise. They can play a key role in training the younger staff, promoting the brand, and providing customers with personal attention. 

However, this group continues to face some serious productivity challenges. Let’s look at what they are and some ways to overcome them. 

Physical Limitations and Issues 

After a certain age, stamina reduces and so does the drive to work. This may have nothing to do with an individual’s passion but their physical health. A woman who is 50 years or older can face a range of health issues, including heart disease and osteoporosis, that may hamper her productivity. 

According to the National Council on Aging (NCOA), a lot of older women face disparities in terms of healthcare access. This will only aggravate the problem. In some cases, there may be no significant health issues involved. Take the example of stress urinary incontinence (SUI), a condition commonly affecting 15.7% of adult women. 

It is the problem of an overactive bladder that may require frequent restroom breaks. This in itself can become a hassle at the workplace. Now, there are some solutions for this problem, but not all are safe as they are effective. 

For instance, a vaginal mesh is often surgically implanted to offer strength and support to the bladder. However, TorHoerman Law states that women have alleged that they suffered severe complications as a result. These include mesh erosion, organ perforation, extreme pain, and infection. 

There is a vaginal mesh lawsuit against the manufacturers filed by over 100,000 injured women. If we keep this solution aside, others like a biological graft repair are available but there are some concerns about their effectiveness. In such cases, one may have to rely on temporary solutions like medications for the time being. 

Women can engage in pelvic floor exercises and bladder training to see better results. However, these take time to have any visible effects. Meanwhile, companies can make provisions by offering older women flexible work schedules. 

Even a hybrid model where they’re allowed to work from home some days of the week is a good option. The policy should be modifiable to ensure older women with a zeal to work are not deprived simply due to health issues out of their control.  

 Stereotypes 

The Conversation published an excellent article addressing the stigma surrounding aging women, especially in the workplace. Shocking as it is, many people, particularly those of the younger generations, consider older women to be anxious and dependent. 

If she is not the CEO, she must surely be wailing in the corner looking to transfer responsibility. Ageism is a real problem in the corporate world and should not be treated as benign. Older women are made to feel diminished, simply for the sake of their age (added over the issue of sexism). 

Companies can put an end to such backward thinking by providing equal work opportunities to young and old women at all organizational levels. Training sessions teaching employees to treat each other with respect must be conducted frequently. Any issues regarding ageism should be dealt with in a serious manner. 

Stereotypes, even if they appear harmless, can take a severe toll on women’s mental health. Over time, productivity gets affected due to stifled creativity, decreased morale, and reduced motivation. 

A Lack of Work-Life Balance 

Having a proper work-life balance is crucial for sustained work enthusiasm. However, many factors can disturb one’s work-life balance, including stress, unrealistic expectations, and workplace conflicts. 

In the case of older women, the previously discussed issues surrounding stereotypes and family obligations can be a major productivity buster. If these women work in service-based organizations where they may have to log in long hours, the issue only escalates. 

When no proper support is available on both sides, the woman may feel trapped, helpless, and lose their enthusiasm for work. There will come a certain point where they may experience chronic burnout. Now, a lack of work-life balance can be a result of family expectations, which is something women must have a serious discussion about. 

However, companies can play a vital positive role in supporting older women by discouraging a culture of overworking. Again, stereotypes should be removed to provide complete autonomy of work. If it is found that a woman is suffering from personal stress, the company can arrange for mental health counseling to help them resolve their issues. 

 The productivity challenges we just discussed are ongoing and will continue as newer generations join the workforce. This is why it is important to lay the groundwork for what diversity and inclusivity truly mean. 

Older women are valuable organizational assets and must not be victims of gendered ageism of any kind. Empathy and compassion go a long way in cherishing them and honoring their year-after-year services.

Share in the comments below: Questions go here

[nurvinaari1]

Navigating Women's Health: The Facts About Transvaginal Mesh & Its Complications

Introduction: In recent years, the use of transvaginal mesh has been a topic of discussion in women's health, particularly in the context of pelvic organ prolapse (POP) and stress urinary incontinence (SUI) surgeries. While transvaginal mesh has been utilized to address these issues, it's essential for women to be well-informed about the procedure and its potential complications. For residents in Thane seeking expert guidance and care, Dr. Sujata Rathod at Nurvi Naari is a trusted gynecologist providing comprehensive women's health services.

Understanding Transvaginal Mesh: Transvaginal mesh is a medical device designed to provide additional support to weakened or damaged tissue in the pelvic region. Surgeons often use it during POP and SUI surgeries to reinforce the vaginal wall and provide structural support to the organs in the pelvic area.

Complications Associated with Transvaginal Mesh: While transvaginal mesh has been used successfully in some cases, it is not without risks. Complications associated with transvaginal mesh may include:

Mesh Erosion: The mesh may erode through the vaginal wall, causing pain, discomfort, and potential infection.

Infection: In some cases, the use of transvaginal mesh can lead to infections, which may require additional medical intervention.

Pain and Discomfort: Patients may experience persistent pain or discomfort, affecting their quality of life.

Urinary Problems: Transvaginal mesh complications may result in urinary issues, such as difficulty emptying the bladder or recurrent urinary tract infections.

Mesh Contraction or Shrinkage: The mesh may contract or shrink over time, leading to further complications.

Gynecologist in Vartak Nagar Thane – Nurvi Naari, Dr. Sujata Rathod: For women in Thane seeking expert guidance on transvaginal mesh or experiencing complications, Dr. Sujata Rathod at Nurvi Naari is a highly regarded gynecologist. With a focus on personalized care and a commitment to women's health, Dr. Rathod and her team offer comprehensive consultations and treatment options tailored to individual needs.

Navigating Women's Health with Expert Care: As awareness grows regarding the potential complications associated with transvaginal mesh, it becomes crucial for women to consult with experienced healthcare professionals. Dr. Sujata Rathod and the team at Nurvi Naari prioritize open communication, ensuring that patients are well-informed about their options and potential risks.

Conclusion: Women's health is a priority, and understanding the facts about transvaginal mesh and its complications is essential for making informed decisions. If you are in Thane and seeking expert care, Nurvi Naari under the guidance of Dr. Sujata Rathod is dedicated to providing comprehensive and compassionate women's health services. Prioritize your well-being and seek professional advice for any concerns related to transvaginal mesh or other women's health issues.

[ayushmanscs1]

TOTs: Transobturator Tape

What Is TOTs Transobturator Tape Treatment?

TOTs Transobturator Tape is a surgical mesh tape used to treat stress urinary incontinence (SUI), a common condition in which urine leaks out when the patient coughs, sneezes or laughs. The TOT is placed under the urethra through small incisions made in the groin area and threaded through the obturator foramen, a small opening in the pelvic bone. The tape acts as a sling to support the urethra and prevent it from moving excessively, thereby reducing or eliminating urinary leakage.

Reasons for TOTs Transobturator Tape Treatment:- Here are some of the reasons why TOT treatment might be recommended.

Stress Urinary Incontinence

TOT surgery is primarily used to treat SUI, which is the involuntary leakage of urine during physical activity, such as coughing, sneezing, or exercising.

Failed Conservative Treatments

If non-surgical treatments such as pelvic floor exercises, bladder training, and medications have failed to relieve the symptoms of SUI, TOT surgery may be recommended.

Desire For Minimally Invasive Treatment

TOT surgery is a minimally invasive procedure that involves only a small incision in the groin area.

Benefits Of TOTs Transobturator Tape Treatment:- Transobturator Tape (TOT) Treatment is a surgical option for women with Stress Urinary Incontinence (SUI), a condition where there is an involuntary leakage of urine during physical activity. Here are some of the benefits of TOT treatment at the Skin & Cosmetic Centre.

Minimally Invasive

TOT surgery is a minimally invasive procedure, requiring only small incisions in the groin area.

High Success Rates

TOT surgery is effective in the treatment of SUI, with long-term success rates of up to 90%.

Fewer Complications

TOT surgery is associated with fewer complications than other surgical treatments for SUI, such as the tension-free vaginal tape (TVT) procedure. Complications such as bladder or bowel injury, vaginal mesh erosion, and back pain are less common with TOT.

Shorter Recovery Time

Most patients can return to normal activities within a few days to a week after TOT surgery, which is much shorter than the recovery time associated with traditional surgical treatments.

What To Do For Recovery After Treatment?

Here are some general tips for recovering after treatment at Skin & Cosmetic Centre in Dwarka Sector 12.

Rest

Rest is important for your body to heal in the first few days after surgery. You may be advised to avoid strenuous activities, heavy lifting and sexual intercourse during this time.

Pain Management

You may experience some pain or discomfort in the groin area after the surgery.

Hygiene

Maintaining good hygiene is important to prevent infection. You may be advised to avoid bathing or swimming until the surgical wound has completely healed.

Follow-up appointments

You will have follow-up appointments with your doctor to monitor your recovery and make sure the surgery was successful.

Conclusion

In conclusion, TOTs Transobturator Tape Treatment is a minimally invasive surgical option for women with stress urinary incontinence (SUI). The benefits of TOT treatment include high success rates, fewer complications, short recovery time, and improved quality of life. Recovery after TOT treatment involves rest, pain management, good hygiene, follow-up appointments, pelvic floor exercises, and maintaining a healthy lifestyle.

[lawyer4help]

HOW TO KNOW IF YOU ARE SUFFERING FROM VAGINAL MESH COMPLICATIONS

Lawyer4Help helps women file Bladder sling lawsuit in USA who have gone through vaginal mesh complications. We provide the best lawyers who have experience in legal proceedings on these cases and reaching a fair settlement.

Pelvic organ prolapse occurs when childbirth and such conditions wear out the tissue in the pelvic area which leads to pain and discomfort. Doctor recommends mesh surgery in the time of an emergency.

Tansvaginal mesh, also known as pelvic mesh or bladder sling. It is a surgical material made of non-absorbable/absorbable synthetic polypropylene that is used to give an extra support to pelvic organ. It is implanted during a surgical procedure for mending a weakened and damaged pelvic organ.

Although, the mesh surgery causes severe complications on account of the problems linked with the procedure. According to FDA, surgical mesh complications are frequent to encounter and ultimately reclassified the use of mesh from moderate to severe risk.

Complications you may face

Frequent complications reported so far from transvaginal surgery include:

● Vaginal mesh erosion

● Infection

● Pelvic and near organ perforation

● Vaginal Shrinkage

● Urinary problems

● Neuro-muscular problem

● Trouble walking

● Fever on and off

● Nausea

● Weight loss

Some of the news reported in the past where women faced urinary issues where every time they laugh, cough, sneeze or part in activities that create extra pressure, causing a small amount of urine to leak. In some cases, it was frequently identified that women wore sanitary pads in defense.

Based on Doctor Raz's experience, 20 to 30% of complications he named as “lupus type”, results in runny nose, muscle pain, fogginess and lethargy.

Primary reason behind facing difficulty is when the mesh starts eroding in the vagina. This makes the mesh slip off of the implanted position and lead to harming pelvic organs and its surroundings.

Symptoms of mesh complications

Vaginal mesh complication symptoms occur within week or month of the surgery which include:

● Painful intercourse

● Vaginal bleeding

● Intensifying urinary incontinence

● Vaginal discharge and pain

These symptoms worsen over time. It’s required to become aware of the symptoms and take prompt actions before it’s late. Besides medical treatment, it’s needed to spread awareness and get justice from it. Bladder Sling lawsuits helped many women and brought them to justice by huge settlements.

Recommendations for women who face complications

Consult a specialist in this area with significant surgical skills and start medical treatment at the earliest.

Other than this as you’ve learned how claiming an amount from companies is beneficial. It not just fulfills your financial loss but stimulates your mental state with a sense of fairness and aids to share knowledge vastly.

Let’s get into a few facts.

Women who have sued companies over vaginal mesh have pulled off success of at least around $300 million. By 2017, many companies had settled thousands of demands for millions of people.

There was a case of Sherise Grant among many women who had faced urinary problems, she pulled off a settlement of $8 billion.

One patient has achieved a victory of $41 million verdict against Johnson & Johnson. Other times the jury awarded millions of dollars to patients. In the meantime, 108,008 lawsuits have been filed in the MDLs and reaching settlements.

In August 2021, FDA banned Boston Scientific and Coloplast devices for transvaginal repair of pelvic organ prolapse to be available for commercial use.

Based on all the factuality, we recommend you to get in touch with the right attorneys on time. Lawyer4Help has experience in giving individuals the power to work out their legal rights in many matters and provides Best lawyers to you.

Settle your Transvaginal mesh lawsuit claims with us. We make things right for you!

[seedsivf]

Laparoscopic Surgery - What is it?

Laparoscopy is a way of performing a surgery. Instead of making a large incision (or cut), our surgeons at Seeds IVF and Fertility Centre make tiny incisions and insert thin instruments and a camera into an area, to view the internal organs and repair or remove tissue.

Laparoscopy is a type of surgical procedure that allows a surgeon to access the inside of the abdomen (tummy) and pelvis without having to make large incisions in the skin. This procedure is also known as keyhole surgery or minimally invasive surgery.

How laparoscopy is carried out

Laparoscopy is carried out under general anaesthetic, so you won't feel any pain during the procedure.

During laparoscopy, the surgeon makes one or more small incisions in the abdomen. These allow the surgeon to insert the laparoscope, small surgical tools, and a tube used to pump gas into the abdomen. This makes it easier for the surgeon to look around and operate.

After the procedure, the gas is let out of your abdomen, the incisions are closed using stitches and a dressing is applied.

You can often go home on the same day of your laparoscopy, although you may need to stay in hospital overnight.

Laparoscopy has many uses, including the diagnosis and treatment of chronic pelvic pain, endometriosis, fibroid tumors, infertility, and ovarian cysts.

Many surgical procedures that used to be performed through larger abdominal incisions are now performed laparoscopically.

Laparoscopic surgery is as safe as traditional open surgery. At the beginning of a laparoscopic operation the laparoscope is inserted through a small incision near the belly button (umbilicus). The surgeon initially inspects the abdomen to determine whether laparoscopy treatment may be safely performed.

Some of the laparoscopic procedures include:

Gynecologic cancer staging

Hysterectomy (removal of the uterus with or without the cervix)

Myomectomy (removal of fibroids)

Sterilization (tubal ligation)

Tubal reanastomosis

Advanced laparoscopic surgeries for pelvic floor disorders, including:

Urinary incontinence (accidental loss of urine)

Fecal incontinence (accidental loss of stool)

Pelvic organ prolapse (including prolapse of the uterus, bladder, small bowel or vagina)

Pelvic pain and pressure

Pelvic floor problems related to childbirth

Frequent urinary tract infections

Sexual dysfunction

Painful intercourse

Issues with bladder and rectal control

Frequent urinary tract infections

Complications related to vaginal prolapse surgery, including vaginal graft/mesh erosion, pain with intercourse, and abnormal vaginal bleeding or discharge

Seeds IVF and Fertility Centre is committed to serve the patients by offering quality health care services endowed with excellence and economy through understanding the patient and future needs.

Are you looking for the Best Laparoscopy Centre near me? Seeds IVF & Fertility Centre is a well-known Test Tube Baby Hospital in Nashik.  We have a team of reputed IVF Specialist doctors who offer multiple fertility treatments for Test Tube Baby, IUI, IVF & ICSI etc.  Open 24x7 hours. Laparoscopy Cost and Success rates and Clinic Reviews, Contact Number and Address for all Laparoscopy Treatments.

Seeds IVF and Fertility Centre

Contact us: +919225669715 | 0253-2377272

Visit us: https://www.seedsivf.com/laparoscopy.php

[baricfunding]

PRE SETTLEMENT LAWSUIT FUNDING FOR VAGINAL MESH – INSTANT RELIEF FROM PAIN

Transvaginal mesh is also called surgical mesh, pelvic mesh or bladder slings. It is used to repair pelvic prolapse (POP) and stress urinary incontinence (SUI). The inconsistencies are removed by repairing the vaginal wall and as a result it relieves incontinence. The complications that arise due to transviginal mesh include bleeding, recurring infection, vaginal discharge and painful intercourse. The vaginal mesh problems arise after some time when the mesh shifts position or mesh erosion. These are classified as not rare side effects by the Food and Drug Administration. It can result in serious discomfort for the patient.

If you are a victim of a faculty vaginal mesh, you need to contact a reputed and experience attorney to evaluate your case. Only a lawyer can explain the potential value of your claim and how it can be achieved. The claim can be either fought in the court or settled out of the court. When it comes to compensation for medical negligence it is a tedious process. But until your claims are cleared pre settlement lawsuit funding for vaginal mesh is your best bet. The good news is the lawsuit funding can cover your medical expenses, mortgage bills and personal expenses.

How to choose the best pre settlement lawsuit funding company for vaginal mesh? In most cases, your attorney will suggest a reliable lawsuit funding company. Baric Enterprises is a trusted name in the field and it comes with loads of features like 24 hours loan, zero repayment if claim is lost, low interest rate, etc. Make the most of the deal and put your life in order.

Sometime compensation can take few months to even years. Money arriving late does not serve the purpose. So, why wait, take the advantage of pre-settlement lawsuit funding for vaginal mesh and get instant relief from pain.

[jesse-pinkman123]

Vaginal Slings Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

Global Vaginal Slings Market Drivers

Increasing prevalence of urinary incontinence is expected to drive global Vaginal Slings Market growth over the forecast period. According to the Global Forum of Incontinence (GFI), in 2018 incidence of urinary incontinence is higher in females compared to males. According to the same source, prevalence of urinary incontinence in women aged 20 and above, is around 12.4% and in around 45% in women over the age of 40. Moreover, majority of these women suffer from daily urinary incontinence and stress urinary incontinence. For instance, according to same source 51% of females suffered from stress urinary incontinence, 11% suffer from urge urinary incontinence, and 17% suffered from mixed urinary incontinence. As a result, high global incidence of urinary continence is expected to drive demand for vaginal slings in the near future.

Vaginal slings placed using minimally invasive procedures are expected to witness significant growth in global vaginal slings market as compared to slings placed using invasive procedures. Key players in the market are focused on launching products for treatment of urinary incontinence. For instance, in 2013, American Medical Systems (AMS) launched the MiniArc Pro single-incision sling system for treating stress urinary incontinence in women. Moreover, Boston Scientific has innovative product line for treatment of urinary incontinence such as Advantage System, Obtryx System, and Lynx System. Moreover, reimbursements for vaginal sling placement procedures are available from organizations such as Centers for Medicare & Medicaid Services (CMS). Such factors are expected to propel global vaginal slings market growth over the forecast period.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2972

Vaginal slings are used to manage urinary incontinence, an undiagnosed condition where an involuntary leakage of urine happens due to losing control of the bladder. Laughing, coughing, sneezing, lifting of heavy things, and exercising are some of the activities that can result in urine leakage. Vaginal slings act like a hammock which upholds and supports the urethra and bladder to prevent leakage. There are several types of slings available in the market such as sub-urethral and pubovaginal slings. Placing pubovaginal slings are minimally invasive surgical procedures (a vaginal incision sling is placed), whereas, sub-urethral slings are placed around the urethra and attached to the abdominal wall.  Sling surgery is a common form of surgery, and slings are made using materials such as human tissue, cadaver tissue, pig or cow tissue, and mesh (synthetic material).

Global Vaginal Slings Market Regional Analysis

North America is expected to dominate the global vaginal slings market growth due to high prevalence of urinary incontinence. For instance, according to the Global Forum of Incontinence (GFI) in 2018, reported prevalence of urinary incontinence in the U.S. is 9%. According to the same source, Europe is expected to support global vaginal slings market growth due to high prevalence of urinary incontinence (9.9%). Moreover, according to same source in Africa, prevalence for urinary incontinence was 7.2%, which is expected to drive the global vaginal slings market growth. The government of Australia initiated a Continence Aids Payment Scheme (CAPS) in 2010, which assists individuals with permanent and severe incontinence by providing financial assistance to support the treatment cost for their continence products.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/vaginal-slings-market-2972

Global Vaginal Slings Market Restraints

One of the major factors restraining growth of the global vaginal slings market is availability of alternative treatments for urinary incontinence over vaginal slings. Alternative treatments include drugs such as anticholinergic, mirabegron, alpha blockers, topical estrogen, and other products such as Transvaginal mesh used by doctors to repair weakened or damaged tissue in the bladder. In 2017, the National Center for Biotechnology Information (NCBI) had reported adverse effects of single incision slings mesh such as vaginal mesh perforations, mesh erosion, and urinary retention. Such factors are likely to result in complete sling removal or partial sling removal as per severity of their side effects. The NCBI also reported complications resulting from sub-urethral slings, such as bleeding, injury to the urethra or bladder, urethral or bladder mesh erosion, vaginal extrusion of mesh, intestinal perforation, and urinary tract infection (UTI).

Global Vaginal Slings Market Key Players

Some of the major players operating in the global vaginal slings market are Boston Scientific Corporation, Coloplast, C.R. Bard, Ethicon, Inc., Betatech Medical, Caldera Medical, Medtronic plc., Analytic Biosurgical solution (ABISS), Agency for Medical Innovations (A.M.I. GmbH), and Promedon Group.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2972

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737

[starclinic]

Mesh / Slings Complications | Star Clinic

https://starclinic.org/content/mesh-slings-complications

Mesh erosion can happen to the adjacent organs, that is when the mesh is felt in the vagina or can be seen in the rectum or bladder.

[rishabhcmi]

VAGINAL SLINGS MARKET ANALYSIS (2020-2027)

Vaginal slings are used to manage urinary incontinence, an undiagnosed condition where an involuntary leakage of urine happens due to losing control of the bladder. Laughing, coughing, sneezing, lifting of heavy things, and exercising are some of the activities that can result in urine leakage. Vaginal slings act like a hammock which upholds and supports the urethra and bladder to prevent leakage. There are several types of slings available in the market such as sub-urethral and pubovaginal slings. Placing pubovaginal slings are minimally invasive surgical procedures (a vaginal incision sling is placed), whereas, sub-urethral slings are placed around the urethra and attached to the abdominal wall.  Sling surgery is a common form of surgery, and slings are made using materials such as human tissue, cadaver tissue, pig or cow tissue, and mesh (synthetic material).

Global Vaginal Slings Market Drivers

Increasing prevalence of urinary incontinence is expected to drive global vaginal slings market growth over the forecast period. According to the Global Forum of Incontinence (GFI), in 2018 incidence of urinary incontinence is higher in females compared to males. According to the same source, prevalence of urinary incontinence in women aged 20 and above, is around 12.4% and in around 45% in women over the age of 40. Moreover, majority of these women suffer from daily urinary incontinence and stress urinary incontinence. For instance, according to same source 51% of females suffered from stress urinary incontinence, 11% suffer from urge urinary incontinence, and 17% suffered from mixed urinary incontinence. As a result, high global incidence of urinary continence is expected to drive demand for vaginal slings in the near future.

Vaginal slings placed using minimally invasive procedures are expected to witness significant growth in global vaginal slings market as compared to slings placed using invasive procedures. Key players in the market are focused on launching products for treatment of urinary incontinence. For instance, in 2013, American Medical Systems (AMS) launched the MiniArc Pro single-incision sling system for treating stress urinary incontinence in women. Moreover, Boston Scientific has innovative product line for treatment of urinary incontinence such as Advantage System, Obtryx System, and Lynx System. Moreover, reimbursements for vaginal sling placement procedures are available from organizations such as Centers for Medicare & Medicaid Services (CMS). Such factors are expected to propel global vaginal slings market growth over the forecast period.

Global Vaginal Slings Market Regional Analysis

North America is expected to dominate the global vaginal slings market growth due to high prevalence of urinary incontinence. For instance, according to the Global Forum of Incontinence (GFI) in 2018, reported prevalence of urinary incontinence in the U.S. is 9%. According to the same source, Europe is expected to support global vaginal slings market growth due to high prevalence of urinary incontinence (9.9%). Moreover, according to same source in Africa, prevalence for urinary incontinence was 7.2%, which is expected to drive the global vaginal slings market growth. The government of Australia initiated a Continence Aids Payment Scheme (CAPS) in 2010, which assists individuals with permanent and severe incontinence by providing financial assistance to support the treatment cost for their continence products.

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/3339

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2972

Global Vaginal Slings Market Restraints

One of the major factors restraining growth of the global vaginal slings market is availability of alternative treatments for urinary incontinence over vaginal slings. Alternative treatments include drugs such as anticholinergic, mirabegron, alpha blockers, topical estrogen, and other products such as Transvaginal mesh used by doctors to repair weakened or damaged tissue in the bladder. In 2017, the National Center for Biotechnology Information (NCBI) had reported adverse effects of single incision slings mesh such as vaginal mesh perforations, mesh erosion, and urinary retention. Such factors are likely to result in complete sling removal or partial sling removal as per severity of their side effects. The NCBI also reported complications resulting from sub-urethral slings, such as bleeding, injury to the urethra or bladder, urethral or bladder mesh erosion, vaginal extrusion of mesh, intestinal perforation, and urinary tract infection (UTI).

Global Vaginal Slings Market Key Players

Some of the major players operating in the global vaginal slings market are Boston Scientific Corporation, Coloplast, C.R. Bard, Ethicon, Inc., Betatech Medical, Caldera Medical, Medtronic plc., Analytic Biosurgical solution (ABISS), Agency for Medical Innovations (A.M.I. GmbH), and Promedon Group.

Global Vaginal Slings Market Taxonomy

By Product Type

Tension-Free Vaginal Tape (TVT) Slings

Transobturator Tape (TOT) Slings

Retropubic Slings

Single Incision Slings

By Urinary Incontinence Type

Urge Incontinence

Stress Incontinence

Mixed Incontinence

By Material Type

Synthetic Slings

Tissue Slings

By End User  

Clinics

Hospitals

Ambulatory Surgical Centers

By Region

North America

Latin America

Europe

Asia Pacific

Middle East

Africa

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2972

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Explore CMI Services here

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Source:

https://www.coherentmarketinsights.com/ongoing-insight/vaginal-slings-market-2972

[perhaps-we-fly]

”We should be concerned if our health system is forced to prioritise convenience and financial targets over wellbeing of its patients. The vaginal mesh is causing chronic burning pain, organ erosion, bladder and bowel perforation, tissue damage, and some women are even left wheelchair-bound or dead. These women’s lives and sex lives are being ruined - but not just theirs. Some report that the mesh has sliced through the vaginal walls, cutting the man’s penis during sex. That ought to finally get everyone’s attention.”

[washingtonmedical-blog]

Advanced Pelvic Surgery Washington DC

Many women and other female-bodied individuals have been ashamed or embarrassed to talk about problems "down there" in the past.  Some of this shame and taboo persist to this day.  It is unfortunate that many folks still have to suffer with unnecessary pain, incontinence, and limited sexual function, among other issues, in the contemporary world where so many good treatment options exist.  Pelvic floor dysfunction has both non-surgical and advanced pelvic surgery Washington DC treatment options.

Types of Advanced Pelvic Surgery Procedures DC

Vaginal mesh implantation is a surgical intervention that is used to treat many kinds of pelvic organ prolapse.  This type of surgery is controversial, and carries a number of risks, including the possibility of a bladder or bowel injury, the erosion of the mesh, chronic pain, and infection.  However, for some patients, the benefits do outweigh the risks.

A hysterectomy is often the most obvious choice for prolapse of the uterus.  For individuals who do not want a hysterectomy, one advanced pelvic surgery DC option DC is called a sacrohysteropexy.  It involves attaching surgical mesh is attached first to the cervix and then to the sacrum to lift the uterus back into place.  This operation carries some of the same risks as placement of mesh within the vagina.

A coloporrhaphy is an operation that can help with prolapsing of the front or back wall of the vagina, or both.  The surgeon places stitches inside of the vagina so that it retains a more typical shape and capacity, and also supports the organs above.

Who Should Consider Surgery?

There are three major factors that help surgical teams and patients make decisions about these types of advanced pelvic surgery DC.  The first of these is age.  Younger patients are more likely to need further procedures as they age.  Childbearing plans have to be considered before any surgery to the reproductive organs is considered.  Most prolapse-correcting surgeries are delayed until after the patient has completed their family in order to avoid damage to the surgical repair during pregnancy and/or childbirth.  Finally, the patient's existing medical conditions always have to be a consideration.  Those who are suffering with obesity, diabetes, heart problems and some other conditions have worse outcomes than those who are otherwise healthy.

[tvm411dotcom-blog]

Are You Aware Of The Latest TVM Update?

Transvaginal mesh, also referred to as a bladder sling, is a popular medical device made of surgical mesh which is meant to support the pelvic organs.

For pelvic organ prolapse (POP) patients, transvaginal mesh is intended to strengthen and support a weakened vaginal wall while holding the pelvic organs in place. POP occurs when the tissues around the pelvic organs begin to weaken or extend, which causes the uterus or bladder to slip out of place commonly through bulging into the vaginal wall.

The device is also designed to provide a similar purpose for women who suffer from stress urinary incontinence (SUI), an involuntary urine leakage which is happens when she is involved in some form of physical activity. In patients with SUI, transvaginal mesh is specifically meant to help support the urethra to help reduce urinary incontinence.

Tens of thousands of women have undergone surgical repair for POP and SUI. These meshes were initially believed to provide a long-lasting, less-invasive option; unfortunately, a growing amount of evidence suggests that transvaginal mesh devices are potentially unsafe and ineffective and can lead to serious health complications. The transvaginal mesh lawsuit update allows the victims of such health issues to fight for their rights and claim for the damage awards.

What did FDA say?

Between 2008 and 2010, the US Food and Drug Administration (FDA) received close to 3,000 reports of adverse complications linked to transvaginal mesh, which is more than double the amount of complaints from 2005 to 2007. From 2008 to 2010, seven deaths associated with POP procedures using transvaginal mesh were reported.

Transvaginal mesh cleared for marketing by the FDA through the 501(k) program meant that it was allowed to be sold based upon the prior approvals of similar mesh products. ProtoGen Sling, a product of Boston Scientific was the first transvaginal medical device to be manufactured,  which was approved in 1996 through the FDA’s 501(k) pre-market approval process for SUI repair. Unfortunately, the FDA never performed any studies to prove whether the transvaginal mesh was safe or effective.

The FDA approved mesh for pelvic organ prolapse repair in 2002 and sales of the product has considerably increased since then. The transvaginal mesh lawsuit update states how the number of reports about the complications also increased with the increase in sales.

In 2008 (which was updated in 2011), the Food and Drug Administration issued a warning about the complications resulting from TVM implants. According to the FDA, these health hazards aren't rare and can need extensive medical treatment.

Brands that have been named in the lawsuit

Johnson & Johnson

American Medical Systems (AMS)

Boston Scientific

 Ethicon

C.R. Bard

Covidien

Johnson & Johnson faces more vaginal mesh lawsuits than any other mesh maker. New Jersey-based C.R. Bard has moved to settle some of the vaginal mesh lawsuits according to the transvaginal mesh lawsuit update. Although there are some more than 10,000 cases which remain unresolved, a few notable verdicts with multimillion settlements have been done. Although there are some more than 10,000 cases which remain unresolved, a few notable verdicts with multimillion settlements have been done.

So if you or someone you know have suffered from the complications of mesh erosion or mesh shrinkage and other undue pain and suffering speak up to find out if your case is eligible for financial compensation.

[loyallogic]

Plaintiff Awarded $68 Million in C.R. Bard Pelvic Repair Mesh Trial

Medical device company, C.R. Bard, suffered a huge loss in New Jersey court over its pelvic mesh products. A Bergen County jury awarded the plaintiff, Mary McGinniss, $33 million in compensatory damages and $35 million in punitive damages against C.R. Bard, with a total award of $68 million. The case of Mary McGinnis v. C.R. Bard, Inc., Docket No.: BER-L-17717-14, New Jersey Superior Court, was the first bellwether trial as part of the state’s mass tort program. With thousands of lawsuits still pending against C.R. Bard and other pelvic mesh manufacturers, the verdict in New Jersey court may be a strong indicator of the future of pelvic mesh litigation.

The Allegations at Trial

The plaintiff, a 62-year old North Carolina resident, alleged that the pelvic mesh device implanted in her to treat pelvic organ prolapse and stress urinary incontinence had caused her chronic pain. The plaintiff used two of Bard’s meshes, the Avaulta and Align.

Soon after implantation, she began suffering from erosion, scar, tissue, dyspareunia, pudendal neuralgia, and loss of bladder functioning. She further alleged that the device, which is clear plastic and made of polypropylene, caused her vaginal tissue to become inflamed. The mesh, which was too large for plaintiff, led her body’s cells to launch protective attacks onto the foreign device, causing damaged tissue in the area. The device, which constricted inside the plaintiff after implantation, proved to be very difficult to completely remove. As a result, the plaintiff underwent three separate mesh removal surgeries which involved extensive groin dissections to remove pieces of the devices. The plaintiff alleged that Bard knowingly disregarded the risks associated with their devices and failed to adequately warn her of the potential dangers. In 2012, Avaulta was taken off the market after the U.S. Food and Drug Administration announced manufacturers were now required to conduct a three-year post-approval monitoring study. In 2016, Align devices were taken off the market as well.

The plaintiff’s attorney put forth evidence that Bard knew its devices were unsafe and failed to adequately warn patients and doctors about the potential dangers. At trial, numerous witnesses with an expertise in medical devices testified. The plaintiff called Adam Silver, the Vice President of Marketing of Bard’s Medical Division and Ronald Bracken, a medical device marketing researcher and former Vice President for Strategic Initiatives for Bard. Bracken is an expert in design controls, failure investigations, 510(k) clearances, test methods, and polymer science. The plaintiff also called Jonathan Conta, a marketing representative for a project team that developed medical devices to treat pelvic organ prolapse. Conta testified that he was responsible for the marketing of the Avaulta Classic device and was aware of the potential side effects, including chronic pain and vaginal erosion. In response to questions concerning the lack of clinical studies, Conta states that: “Any product marketer would want as much clinical data as they could get, and I always wanted more.”

Dr. William R. Welch, a surgical pathologist, testified that the amount of scar tissue found in the plaintiff was abnormal. Dr. Elizabeth Barbee, the gynecologist who implanted the device into the plaintiff, testified that she received training from Bard which included practice on a human cadaver. Barbee testified that she advised plaintiff of the potential side effects but did not believe that such side effects would lead to a catastrophic condition that could not be safely and effectively treated. Bard countered these allegations by maintaining that its products were extensively tested and that the plaintiff’s injuries were caused by other underlying medical conditions.

The defendant’s arguments proved to be unpersuasive as the jury found in favor of the plaintiff and awarded a total of $68 million in damages, making it the highest paid verdict thus far in Bard pelvic mesh litigation. Bard previously went to trial in other pelvic mesh cases. Jury trials in the state courts of California and West Virginia returned verdicts of $5.5 million and $2 million, respectively. A 2016 Missouri state court trial, however, found in favor of the defense.

Other Pelvic Mesh Litigation

According to its regulatory filings, Bard has settled more than 13,000 cases since 2014, with more than 500 lawsuits settling for $21 million in 2014 and another 3,000 cases settling for $200 million in 2015. However, Bard’s days in court are far from over. There are still more than 3,000 pending lawsuits against Bard, which were consolidated before a federal judge in West Virginia, along with 150 lawsuits in New Jersey state courts.

Bard is not the only medical device manufacturer facing hefty litigation over its pelvic mesh products. Both Johnson & Johnson and Boston Scientific, two major medical device manufacturers, have been litigating similar issues for the past few years.

In November 2014, Boston Scientific lost major two products liability trials. On November 13, 2014, a Florida jury awarded $26.7 million to four plaintiffs who were implanted with the company’s Pinnacle mesh devices. Within the same week, a West Virginia jury awarded $18.5 million to plaintiffs who suffered injuries from Boston Scientific’s Obtryx mid-urethral slings, which included $4 million in punitive damages.

Johnson & Johnson, along with its Ethicon mesh products, have been named defendants in more than 55,000 transvaginal mesh lawsuits. Similar to the allegations against bard, the plaintiffs are all women who suffered complications such as mesh erosion, scarring, and organ damage. A majority of lawsuits have been consolidated in multidistrict litigation in the United States District Court of the Southern District of West Virginia. A number of lawsuits are also pending in the Pennsylvania mass tort program. In January 2016, Johnson & Johnson agreed to pay $120 million to settle thousands of mesh lawsuits. The cases that have proceeded to trial and resulted in favorable verdicts for the plaintiffs had awarded damages in the amounts of $20 million, $12.5 million, $13.5 million, and $2.1 million.

New Jersey is the home of the U.S. headquarters for both Johnson & Johnson and Bard, making the state a major hub for pelvic mesh litigation. It is likely that the recent Bard verdict will have implications for the remaining pelvic mesh lawsuits, particularly those pending in New Jersey.

The post Plaintiff Awarded $68 Million in C.R. Bard Pelvic Repair Mesh Trial appeared first on The Expert Institute.

Plaintiff Awarded $68 Million in C.R. Bard Pelvic Repair Mesh Trial published first on https://namechangers.tumblr.com/

[lawyer4help]

THE TRUTH BEHIND TRANSVAGINAL MESH LITIGATION

A vast number of women have taken legal action against the transvaginal mesh in recent years. The lawsuits have alleged various physical complications and autoimmune problems caused by the transvaginal mesh.

Here, the claims on transvaginal mesh filled in the U.S. are analyzed to identify their characteristics for clinical decision making.

What Is Transvaginal Mesh?

Transvaginal mesh is a net-like synthetic surgical tool used to treat pelvic organ prolapse among female patients. Organ pelvic prolapse is a condition that makes women leak from their bladder while doing activities like running, jumping or even sneezing and coughing.

It provides extra support to repair damaged or weakened internal tissues. It is implanted in the vagina vis surgical procedure. Transvaginal mesh can be also be known as sling, tape or hammock. It is usually impossible to remove the implant after it has been implanted.

Problems Described in the Transvaginal Litigation

Women who received the implant filed lawsuits claiming that they suffered from painful injuries. The complications include pain, bleeding, organ perforation, infection and autoimmune problems. According to the lawsuit, these ladies experienced issues walking, sitting, and engaging in other high-impact activities.

The problems described by the women who received the implant were so bad that they had to suffer multiple revision surgeries to remove the implant. Studies show that bacterial infections can grow on the implants.

The implant damages internal organs causing erosion in the vaginal wall. In addition, the implant cuts through tissues and damages nerves that cause pain during impact activities. In some claims, the mesh blocks the bladder, which causes urinary problems.

Studies show that in most cases, the complications were relatively minor. However, in some cases, the complications were severe. Studies also show that the implant can fail even after surgery, causing recurring prolapse. Some women even experience worsened unitary incontinence.

Allegations against Manufacturers

Five companies manufactured transvaginal mesh in the United States. American Medical System, Boston Scientific, C.R. Bard, Ethicon and Proxy Biomedical are transvaginal mesh manufacturers.

The lawsuit claims that the manufacturer had a legal duty to ensure the safety and effectiveness of its products. But the patients were misled with false information. According to a study in 2017, the products were cleared against the charge based on weak evidence.

● Lack of proper test of the implant

● Lack of research on the risk of the implant

● Failing to create a compelling and safe method to remove the implant

● Inadequate in waring the potential complications and injuries to the patients

● Misleading the patients, medical community and the public about the effectiveness of the product

The manufacturing companies have agreed to settle outstanding lawsuits and have set aside hundreds of millions of dollars for this. As of November 2019, Ethicon faced 1,202 lawsuits, followed by Boston Scientific with 965, American Medical with 80 and Bard with 16.

Current Controversy Surrounding Transvaginal Mesh

As of November 2019, more than 108,000 lawsuits have been filed against the mesh manufacturer.

More than 2,263 lawsuits are still pending. One of the largest settlements to date was $830 million for 20,000 claims.

In 2019, the U.S. Food & Drug Administration stopped all sales of transvaginal mesh for pelvic organ prolapse treatment. In the short-term clinical trial, studies found high efficiency and low complication rate in the transvaginal mesh implant for unitary incontinence. However, there is huge evidence of low efficiency and high complication rate for pelvic organ prolapse treatment.

The UK NHS study shows that one in 15 women who had the implant later removed them surgically. In a survey of 2,220 women who received the transvaginal mesh implant, 59% said that the treatment did not resolve the original issue. 58% of women said that they experienced pain during physical activity.

Settlement and Verdicts

So far, mesh manufacturers have paid billions for the lawsuit settlements. As of February 2019, 32 women had filed cases in the state court, out of which 24 women received a jury award of $345 million. The mesh manufacturer has paid $8 billion in settlement of the lawsuit.

As of March 2021, Boston Scientific agreed to settle deceptive marketing claims by paying $188.7 million.

Final words!

The transvaginal mesh litigation involves a sling for the procedure. However, the rise in the lawsuit does not reflect low complication rates in the report. The complication seems to be expected in women who had received the implant to treat pelvic organ prolapse.

New treatments are trialled on patients when other treatments have proven ineffective. However, patients should always be informed about the treatment and its efficiency to give informed consent for the procedure.

The patient should be comfortable asking their specialist about the procedure and complication rates. They should feel comfortable with the evidence that the surgery will work.

[cochranlaw]

The Status of Vaginal Mesh Surgery in the UK

Vaginal mesh lawsuits have been common in the United States due to a large number of women sustaining permanent injury as a result of procedures using the mesh.

 Last year, the National Health Service (NHS) in the UK issued a temporary ban on using surgical mesh. Recently, the National Institute for Health and Care Excellence (NICE) has issued a statement that lifts the ban if the use meets certain conditions.

 What Is Vaginal Mesh?

Vaginal mesh is a net used to treat pelvic organ prolapse. Pelvic organ prolapse is when weakened tissue causes a woman’s bladder, uterus or rectum descends and pushes on the vagina.

 This condition causes incontinence and can make going to the bathroom, sex, and sports difficult and sometimes impossible.

 Doctors began using what is now called transvaginal mesh in the 1950s for hernias. 

By the 1970s doctors had begun using it for pelvic organ prolapse, and by the 1990s gynecologists began surgically treating incontinence in women.

 The Food and Drug Administration (FDA) approved its use formally in 2002.

What Is Vaginal Mesh Made of?

Mesh is made from polypropylene plastic, although some companies have made mesh out of animal tissue.

 FDA Warnings

In about 2007, the FDA began receiving multiple reports of transvaginal mesh complications. In 2008 the FDA issued an alert to doctors identifying serious patient safety concerns and adverse side effects. By 2019 the FDA warnings and compliance requirements effectively stopped most companies in the U.S. market from manufacturing and selling the mesh.

 Types of Complications

The mesh would sometimes erode and start to penetrate the vaginal wall. Women would experience bleeding, pain during sex, and even reports of partners getting scratched during intercourse from pieces of plastic that had penetrated the vagina. Removing the mesh is virtually impossible. To correct the erosion problem women sometimes underwent two or three surgeries.

 UK Temporary Ban

In 2018 the UK put in place a temporary ban on the NHS performing the procedure. 

During the preceding decade, 1 in 15 British women had to have the implant removed due to serious complications. Over 7% of the women who had vaginal mesh surgery required at least one more surgery to treat their pelvic organ prolapse.

 Hundreds of thousands of lawsuits have been filed due to complications with the surgery.

The American subsidiary of Johnson and Johnson, Ethicon, provides a popular type of vaginal mesh that was used for years by UK, American, and U.S. surgeons.

The company halted production of the mesh in 2016, but since then thousands of women in Australia and America have joined class action lawsuits against the company.

 Scottish Concerns

As early as 2014, the Scottish Health Secretary required the health boards suspend using mesh throughout the UK. At the time, the NHS believed that the evidence in the UK did not suggest any long-term complications for most women. Hundreds of women began filing lawsuits against the NHS, and by 2018, the high rates of removal and reports of complications eventually caused the NHS to issue a temporary ban.

 NICE Approves Reinstatement with Conditions

Despite the number of lawsuits and growing concerns among UK healthcare professionals that had previously supported mesh operations, the National Institute for Health Care and Excellence has recommended the NHS allow the surgery once again.

The new restrictions permit only specialist surgeons operating in specialist centers to perform the operation.

 All transvaginal mesh surgeries in the future must be added to a national data base.

The NICE recommendation only applies to the NHS in England. Observers expect NHS to accept the advice and restart the surgeries before the end of 2019.

[legalroll]

How Experts Helped Win the Biggest Verdicts of 2018

The importance of expert testimony at a trial cannot be overstated, as it oftentimes provides the edge one needs to win a scientifically complex case. The year 2018, in particular, saw some substantial verdict awards, which were earned in no small part due to expert testimony.  Below are just a few examples of how expert testimony shaped the litigation landscape in 2018.

$4.7 Billion Verdict Against Johnson & Johnson for Baby Powder’s Link to Ovarian Cancer

The allegation that manufacturing giant, Johnson & Johnson, sells products contaminated with asbestos is not new. Internal company documents, which were exposed in December 2018 in special reports conducted by Reuters and the New York Times, indicated that Johnson & Johnson knew from at least 1971 that the company’s talc and Baby Powder products tested positive for small amounts of asbestos but failed to disclose this fact to the public. The 22 plaintiffs (6 of which were deceased) in Ingham, et al. v. Johnson & Johnson, et al., were some of the first to successfully argue the link between Johnson & Johnson Baby Powder products and ovarian cancer. The Missouri jury awarded the plaintiffs $4.7 billion in damages, which was notably upheld by the Circuit Court of Missouri, making it the sixth-largest products liability verdict in U.S. history.

With the company insisting that their products were safe, the verdict in Ingham was undoubtedly won by the plaintiffs’ experts who conducted their own tests to prove that the talc products were contaminated with asbestos. Medical experts testified that asbestos, a known carcinogen, was intermingled with mineral talc, and that asbestos fibers and talc particles were found in the ovarian tissues of the plaintiffs. With over 10,600 lawsuits pending against Johnson & Johnson alleging that their products cause ovarian cancer, the plaintiffs’ experts in Ingham have provided the groundwork for the success of any future trials.

$117 Million Verdict Against Johnson & Johnson in Mesothelioma Trial

With similar allegations of misconduct but different injuries, Johnson & Johnson took another substantial hit in Lanzo v. Imerys Talc America when a New Jersey jury awarded the plaintiff $117 million in damages after developing mesothelioma from Johnson & Johnson’s Baby Powder products. Mesothelioma, a type of cancer that affects the lining of the lungs, abdomen, and heart, has long been considered to be caused by industrial talc products. Allegations that cosmetic talc products cause mesothelioma, however, are relatively novel. Similar to the Ingham case, the plaintiff in Lanzo proved, through the company’s own internal documents, that Johnson & Johnson knew for decades that their talc products were contaminated with asbestos but hid this fact from consumers. The defendant’s knowledge and failure to warn about this risk was corroborated by its own corporate representatives, who testified that the company knew since the 1960s that asbestos exposure causes cancer. Dating back as far as 1969, Johnson & Johnson’s medical doctor warned the company to limit asbestos content in their powder products. Notably, the defendant’s own experts conceded at trial that a 1991 report indicating that certain brands of Baby Powder products contained asbestos had proven that the company’s products were contaminated.

The plaintiff’s expert, Dr. William Longo, conducted his own tests on bottles of Johnson & Johnson Baby Powder. He found that the talc contained in the products, which was mined from China, was contaminated with asbestos. Through the help of an electron microscope, the plaintiff’s expert testified that he found asbestos in more than half of the 32 samples he examined. With mixed success in previous trials (the company has won three mesothelioma cases, with four others being declared mistrials), the Lanzo verdict may signify a change in the tides for plaintiffs.

$289 Million Verdict Against Monsanto’s Roundup Weed Killer

Class action lawsuits against the agrochemical giant, Monsanto, have been accruing for years as plaintiffs allege the company’s Roundup herbicide product is toxic and unsafe. With thousands of cases consolidated by the United States Judicial Panel on Multidistrict Litigation for the Northern District of California, the case of Johnson v. Monsanto was the first of its kind to go to trial. The plaintiff, a 46-year old school groundskeeper, alleged that the company’s weed killers caused him to develop non-Hodgkin’s lymphoma. The lawsuit, filed in 2016 and acting as a bellwether for future Roundup litigation, was fast tracked for trial because of the severity of the plaintiff’s cancer, with doctors tragically estimating he was unlikely to live past 2020. After deliberating for three days, the San Francisco jury found in favor of the plaintiff and that Monsanto failed to warn him and other consumers about the cancer risk associated with its products. The jury awarded the plaintiff $39 million in compensatory damages and $250 million in punitive damages, the latter of which was cut down by a San Francisco judge to $39 million.

At trial, the plaintiff presented numerous independent studies and experts to establish that glyphosate, the main ingredient in Roundup, causes various types of cancer. The jury found the scientific evidence credible and compelling, and also found that Monsanto acted with malice by repeatedly rejecting expert research and warnings. With 4,000 similar cases pending before state and federal courts, the Johnson v. Monsanto verdicts could set a precedent for future litigation.

$68 Million Verdict Against C.R. Bard for Pelvic Mesh Medical Devices

Medical device company, C.R. Bard, suffered a huge loss in New Jersey court when a jury awarded the plaintiff $68 million in damages due to a defective pelvic mesh implant. The case of Mary McGinnis v. C.R. Bard, Inc. was a bellwether trial as part of New Jersey’s mass tort program. The plaintiff alleged that two of C.R. Bard’s pelvic mesh devices, which were implanted inside of her to treat pelvic organ prolapse and stress urinary incontinence, had caused her chronic pain and other injuries. After implantation, she began suffering from dyspareunia, pudendal neuralgia, and loss of bladder functioning. She alleged that the device, which is made of polypropylene, caused inflammation of her vaginal tissue. Because the mesh was not the proper size and was too large, it caused her body’s cells to launch protective attacks onto the device, damaging surrounding tissue. The device constricted inside the plaintiff after implantation. As a result, the plaintiff underwent three separate mesh removal surgeries, which involved extensive groin dissections to remove pieces of the devices. The two devices implanted in the plaintiff, Avaulta and Align, have been taken off the market in 2012 and 2016, respectively.

At trial, in order to establish the plaintiff’s injuries, Dr. William R. Welch, a surgical pathologist, testified that the amount of scar tissue found in the plaintiff was abnormal. The gynecologist who had implanted the device also testified as to the expected side effects. In addition, several plaintiff experts were used to establish that the pelvic mesh devices were unsafe and that C.R. Bard failed to adequately warn patients and doctors about the potential dangers. Ronald Bracken, a medical device marketing researcher and former Vice President for Strategic Initiatives for Bard, testified as to the design controls, failure investigations, 510(k) clearances, test methods, and polymer science. The plaintiff also called Jonathan Conta, a marketing representative for a project team that developed medical devices to treat pelvic organ prolapse. Conta testified that he was responsible for the marketing of the Avaulta Cassic device and was aware of the potential side effects, including chronic pain and vaginal erosion. In response to questions concerning the lack of clinical studies, Conta stated that: “Any product marketer would want as much clinical data as they could get, and I always wanted more.”

C.R. Bard has settled more than 13,000 cases since 2014. There are still more than 3,000 pending lawsuits against the company, which were consolidated before a federal judge in West Virginia, along with 150 lawsuits in New Jersey state courts.

The post How Experts Helped Win the Biggest Verdicts of 2018 appeared first on The Expert Institute.

How Experts Helped Win the Biggest Verdicts of 2018 published first on https://medium.com/@SanAntonioAttorney